Vanta Bioscience shareholders and shareholding pattern
BSE: 540729Healthcare ServicesSmall Cap
Vanta Bioscience Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2017
Last close ₹20.39down ₹0.01 (0.05%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹20.40.
30 Oct: open ₹20.39, high ₹20.39, low ₹20.39
52-week range of traded prices to 30 Oct 2026
₹14.71Low, 24 Mar 2026₹29.00High, 6 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15 Cr4,396th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 133.90
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.80
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 750
Vanta Bioscience's shareholding pattern for Sep 2026, filed on 21 Oct 2026, with every filing from Mar 2018: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Vanta Bioscience, filing by filing
Per cent of the company's shares.
30 Sep 2026 filing
- Promoters72.81%
- Individuals and others27.19%
| Per cent | Mar 2018 | Sep 202630 Sep |
|---|---|---|
| 72.45% | 72.81% | |
| Indian promoters | 72.45% | 72.81% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 27.55% | 27.19% |
| Shares in issue | 57,28,000 | 71,12,000 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 42,16,000 | 8,00,000 |
| Promoters' shares locked in | 41,50,000 | 8,00,000 |
Filings before Sep 2026 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state.
Vanta Bioscience promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing of 30 Sep 2026; the largest is MOHAN KRISHNA MULAKALA, 49.01%.Promoter buying and selling
| Holder | |||
|---|---|---|---|
| MOHAN KRISHNA MULAKALAIndividuals and Hindu undivided families | 49.01% | 34,85,500 | 0.00% |
| DOPESH RAJA MULAKALAIndividuals and Hindu undivided families | 12.06% | 8,58,000 | 46.62% |
| S CHANDRA SEKHAR RAOIndividuals and Hindu undivided families | 7.35% | 5,22,500 | 76.56% |
| SOUMYA SIMHADRIIndividuals and Hindu undivided families | 1.27% | 90,100 | 0.00% |
| SHRAVAN CHINTAPATLAIndividuals and Hindu undivided families | 1.13% | 80,100 | 0.00% |
| MULAKALA KARISHMAIndividuals and Hindu undivided families | 0.70% | 50,100 | 0.00% |
| VYASMURTI MADHAVRAO SHINGATGERIIndividuals and Hindu undivided families | 0.70% | 50,000 | 0.00% |
| PRADEEP CHOWDARY VEERAMACHINENIIndividuals and Hindu undivided families | 0.30% | 21,500 | 0.00% |
| M SAJAN KIRANIndividuals and Hindu undivided families | 0.28% | 20,100 | 0.00% |
| SUJANA SHEELA MULAKALAIndividuals and Hindu undivided families | 0.00% | 100 | 0.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Vanta Bioscience, filing by filing
Per cent, on the same shares as the split above.
| Holder | Mar 2018 | Sep 202630 Sep |
|---|---|---|
| INVENTURE GROWTH & SECURITIES LTD.Other non-institutions | 1.52% | – |
| M REKHAResident individuals, over ₹2 lakh at face value | 1.47% | – |
| KIRANMAYI K .Resident individuals, over ₹2 lakh at face value | 1.05% | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.